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Abstract
Background: Autism comprises a spectrum of behavioral and cognitive disturbances of childhood
development and is known to be highly heritable. Although numerous approaches have been used
to identify genes implicated in the development of autism, less than 10% of autism cases have been
attributed to single gene disorders.
Methods:  We describe the use of high-resolution genome-wide tilepath microarrays and
comparative genomic hybridization to identify copy number variants within 119 probands from
multiplex autism families. We next carried out DNA methylation analysis by bisulfite sequencing in
a proband and his family, expanding this analysis to methylation analysis of peripheral blood and
temporal cortex DNA of autism cases and matched controls from independent datasets. We also
assessed oxytocin receptor (OXTR) gene expression within the temporal cortex tissue by
quantitative real-time polymerase chain reaction (PCR).
Results: Our analysis revealed a genomic deletion containing the oxytocin receptor gene, OXTR
(MIM accession no.: 167055), previously implicated in autism, was present in an autism proband and
his mother who exhibits symptoms of obsessive-compulsive disorder. The proband's affected
sibling did not harbor this deletion but instead may exhibit epigenetic misregulation of this gene
through aberrant gene silencing by DNA methylation. Further DNA methylation analysis of the
CpG island known to regulate OXTR expression identified several CpG dinucleotides that show
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independent statistically significant increases in the DNA methylation status in the peripheral blood
cells and temporal cortex in independent datasets of individuals with autism as compared to control
samples. Associated with the increase in methylation of these CpG dinucleotides is our finding that
OXTR mRNA showed decreased expression in the temporal cortex tissue of autism cases matched
for age and sex compared to controls.
Conclusion:  Together, these data provide further evidence for the role of OXTR and the
oxytocin signaling pathway in the etiology of autism and, for the first time, implicate the epigenetic
regulation of OXTR in the development of the disorder.
See the related commentary by Gurrieri and Neri: http://www.biomedcentral.com/1741-7015/7/63
Background
Classic autism comprises a spectrum of behavioral and
cognitive disturbances of childhood development. The
core autism phenotype includes deficits in social interac-
tion, language development and patterns of repetitive
behaviors and/or restricted interests. The population prev-
alence of the spectrum of autism disorders is estimated to
range between 1/300 [1] to 1/100 http://www.nsch
data.org/, with a male: female ratio of 4:1 [2,3]. The disor-
der has been shown to be highly heritable with the relative
risk for siblings being approximately 2% to 8%, much
higher than that of the general population [4]. To date,
only a small percentage of autism cases (<10%) have been
ascribed to single gene disorders such as fragile X syn-
drome, tuberous sclerosis [5] and Rett syndrome [6].
Numerous approaches including genetic linkage,
genome-wide association, candidate gene association and
gene expression analysis have been used to identify the
additional genes implicated in the development of autism
[7,8]. However, the heterogeneous nature of autism and
autism spectrum disorders has limited their success.
An additional approach to identify genes involved in
autism is to characterize copy number variants (CNVs),
that is, chromosomal deletions and duplications, that are
known to be present within at least 5% of individuals with
idiopathic autism [9]. Autism CNVs have been shown to
involve almost all chromosomes [10,11], with the most
frequently observed alteration localizing to chromosome
15q11-13 [12-23]. A number of different methods have
been used to characterize autism related CNVs, including
but not limited to, cytogenetic G-banding [14,23,24],
metaphase fluorescence in situ hybridization (FISH) [22],
Southern blotting [18], loss of heterozygosity (LOH) anal-
ysis [15-17,19], quantitative polymerase chain reaction
(PCR) [25] and, more recently, genotyping and represen-
tational oligonucleotide microarray analysis (ROMA)
[26].
Here we describe the use of genome-wide tilepath micro-
arrays and array comparative genomic hybridization
(CGH) to identify CNVs in a dataset of 119 unrelated
probands from multiplex autism families [27]. The
genomic profiles of our autism dataset were compared to
the array CGH profiles of 54 phenotypically normal indi-
viduals, to previously published CNVs present within the
database of genomic variants [28] and to the Autism
Chromosome Rearrangement Database http://
projects.tcag.ca/autism/. The most significant finding thus
far from our analysis is a heterozygous deletion of the oxy-
tocin receptor gene (OXTR) (MIM accession no.: 167055)
in an individual with autism and his mother with putative
obsessive-compulsive disorder (OCD). We further investi-
gated the relationship between OXTR and autism by car-
rying out epigenetic analysis of the promoter region of
OXTR. We show that the gene is hypermethylated in inde-
pendent cohorts with autism as compared to controls, in
both peripheral blood mononuclear cells (PBMCs) and
the temporal cortex. Additionally, our analysis of expres-
sion levels of OXTR  in the temporal cortex shows
decreased levels of expression in individuals with autism
as compared to controls matched for age and sex.
These data suggest that OXTR and the oxytocin signaling
pathway play an important role in the etiology of autism
and autism spectrum disorders and implicate epigenetic
misregulation of OXTR in this complex disease.
Methods
Diagnostic and Statistical Manual of Mental Disorders 
criteria
Research diagnostic classification entailed the collection
of detailed family, developmental, and medical history
and systematic screening of each child with autism before
proceeding with clinical assessments. The clinical diagno-
sis of autism was confirmed by standardized diagnostic
assessments once a family had completed the screening
process and was considered eligible. For research classifi-
cation, a clinical diagnosis that conforms to Diagnostic
and Statistical Manual of Mental Disorders, fourth edition
(DSM-IV) criteria was made based on all available medi-
cal, clinical, and behavioral data. The clinical diagnosis
was established as a research diagnosis on the basis of
scores that exceed established cut-offs for autism on the
Autism Diagnostic Interview-Revised (ADI-R) [29,30]. In
addition, all individuals demonstrated a minimum IQBMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
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equivalent of 35 or Vineland Adaptive Behavior Scale age
equivalent of 18 months. This ensured a sufficient devel-
opmental level for reliable classification on diagnostic
measures. All instruments were administered by clinical
staff that had been formally trained on all measures and,
as appropriate, had demonstrated reliability within the
research group as well as at clinical centers. All individuals
are qualified only after review of materials by a licensed
child psychologist (MC). Parents/caregivers were
informed of the purposes, risks, and benefits of participat-
ing in this project and provided informed consent.
Peripheral blood collection
All aspects of the research study were approved by the
Institutional Review Boards of the participating centers.
DNA for copy number and methylation analyses was
obtained from the peripheral blood of autism probands
from multiplex families, the extended family of the
proband with the OXTR deletion, and phenotypically nor-
mal controls. Genomic DNA was extracted from whole
blood using the Pure Gene method and standard proto-
cols, as described previously [31]. DNA for the methyla-
tion analysis was collected from 20 autism cases and
controls, all individuals were Caucasian, and the male to
female ratio was 1:1.
Autism brain tissue
Postmortem studies were performed using frozen brain
tissue samples dissected from the superior temporal gyrus
(BA 41/42) of eight patient-control pairs, obtained
through the Autism Tissue Program from the Maryland
National Institute of Child Health and Human Develop-
ment (NICHD) Brain Tissue Center and the Harvard Brain
Tissue Resource Center (Table 1). This neocortical region
was chosen because it hosts well documented structural
and functional abnormalities in autism [32-35]. These tis-
sue samples largely overlap with those employed in our
recent studies of the MET  and  PRKCB1  genes [36,37].
Clinical and demographic information, family history,
and autopsy reports were obtained from the Autism Tissue
Program web site http://www.atpportal.org and are sum-
marized in Table 1. The presence of mental retardation
was defined on the basis of a full-scale IQ <70. Autism
spectrum disorder cases fulfill DSM-IV diagnostic criteria
[38], confirmed using the ADI-R [29,30]. Although the
methylation study was not planned according to a
matched design, all controls were selected to match
patients on sex, age (± 2 years, wherever possible) and
postmortem interval (PMI), where possible (Table 1).
Array hybridization
High-resolution genome tilepath microarrays were con-
structed using large bacterial clones (bacterial artificial
chromosome (BAC) clones) as previously described [39].
Briefly, BAC DNA was purified by alkaline lysis and used
as the template for three different, degenerate oligonucle-
otide primed PCR reactions, prior to a second round of
amino linking PCR and printing onto Codelink slides (GE
Bioscience, Piscataway, NJ, USA) using a Genetix Qarray2
(Genetix, Boston, MA, USA). A total of 450 ng of autism
Table 1: Description of clinical details associated with the temporal cortex tissue used in the methylation and expression analyses
Case no. Sex Age (years) PMI (h) Diagnosis Cause of death
Controls:
UMB-1185* M 4 17 Control Drowning
UMB-1860* M 8 5 Control Cardiac arrhythmia
B-3829* M 22 24 Control Central hepatic laceration
UMB-1706* F 8 20 Control Rejection of heart transplant
UMB-1377 F 5 20 Control Drowning
B-6207 M 16 26 Control Ischemic heart attack
B-6221 M 22 24 Control Unknown
B-5873 M 28 23 Control Unknown
B-4211 M 30 23 Control Cardiac arrhythmia
Autism:
B-5569* M 5 25.5 PDD-NOS Drowning
UMB-4721* M 8 16 Autism Drowning
B-5144* M 20 23.7 Autism Traffic accident
UMB-4671* F 4 13 Autism Accident
UMB-1174 F 7 14 Autism Sudden death, seizure
B-6294 M 16 Unknown Autism Unknown
B-6337 M 22 25 Autism Choking
B-5000 M 27 8.3 Autism Drowning
B-5173 M 30 20 Autism Gastrointestinal hemorrhage
Paired samples for expression analysis are denoted by an asterisk. Italicized samples were excluded from the methylation analysis to maintain 
phenotypic homogeneity.
PMI = postmortem interval; PDD-NOS = Pervasive Developmental Disorder Not Otherwise Specified.BMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
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proband and control DNA, from peripheral blood, were
differentially labeled with Cy3-CTP and Cy5-CTP (Bio-
Prime Labeling Kit; Invitrogen, Carlsbad, CA, USA), puri-
fied (Qiagen, Hilden, Germany) and hybridized to the
tilepath arrays using the MAUI hybridization station
(BioMicro Systems Inc, Salt Lake City, UT, USA). Image
capture of the hybridized arrays for fluorescent intensity
extraction was performed using a Genepix 4100A scanner
(Molecular Devices, Sunnyvale, CA, USA) and Bluefuse
microarray software (BlueGnome http://www.cambridge
bluegnome.com/bluefuse_micro) was used for data
processing of the scanned images prior to porting into
Nexus (BioDiscovery http://www.biodiscovery.com/
index/nexus) for analysis.
Array CGH analysis
Microarray data was preprocessed in Nexus by removing
poor quality flagged spots (confidence <0.3 as defined by
Bluefuse software), removing background by Lowess cor-
rection before normalization of log2 ratios and combining
BAC replicates. BioDiscovery's rank segmentation algo-
rithm (RSA), which is similar to circular binary segmenta-
tion (CBS) [40], was used to identify genomic
rearrangements. Briefly, the algorithm uses a normal dis-
tribution function for testing for change points as
opposed to the non-parametric permutation based statis-
tics used in the original CBS algorithm. It also uses the log
ratio rank of each probe as oppose the log ratio value
itself. The calling algorithm used cluster values and
defined log2 thresholds of ± 1.4 and 0.38 for two and one
copy gain/loss, respectively. We applied a conservative
cut-off of three BAC clones showing the same copy
number change trend to define genomic deletion or
duplication with the significance threshold set at 0.005.
Array CGH dye-swap experiments were carried out on 21
samples to confirm 21 genomic changes, including novel
and known CNVs within the database of genomic vari-
ants.
Quantitative real-time PCR validation
DNA copy number was validated using the Applied Bio-
systems 7900 HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Primers and probes
were designed to a region spanning exon 2 in OXTR: for-
ward 5'-GCTGAACATCCCGAGGAACTG-3' and reverse
5'-GCAAATGAGCGGGAATCCTCTA-3'. DNA samples
from autistic probands and their family members were
used to determine if the CNV was familial or de novo. DNA
isolated from tumor samples with known deletions at the
regions containing OXTR were used as 1 × copy number
controls and an unaffected individual identified in our
normal-normal CGH experiment served as our 2 × copy
number control at these loci. A primer and probe set
designed to the single copy gene that encodes the RNA
moiety for the RNase P enzyme, RPPH1 (MIM accession
no.: 608513), a region of stable copy number (2 ×), was
used to normalize each sample for equal input. Copy
number was assessed in quadruplicate for each sample
and the 2-ΔΔC
T method was used for analysis [41].
Microsatellite screening
Microsatellite markers were analyzed in the family carry-
ing the deletion of OXTR to determine maternal or pater-
nal contributions. Five markers on chromosome 3
(D3S1489, D3S18, D3S4539, D3S4163, D3S3691) were
fluorescently labeled using PCR (primers indicated in
Additional file 1) and size fractionated on an Applied Bio-
systems 3730 capillary sequencer (Applied Biosystems,
Foster City, CA, USA). Then, 1 μl of the PCR product was
diluted 1/70 and run on an agarose gel to confirm ampli-
fication, and 1 μl of the diluted PCR product was added to
19 μl of HiDye Formamide/LIZ 500 Standard solution
and loaded on to the capillary sequencer and analyzed
using standard software.
Methylation analysis
DNA isolated from blood or brain samples was bisulfite
converted using a methylSEQr Bisulfite Conversion Kit
(Applied Biosystems, Foster City, CA, USA). Primers were
designed to bisulfite-converted regions of CpG islands in
the promoter region of the OXTR gene and in the third
intron that had previously been shown to exhibit different
patterns of methylation among individuals [42] (Addi-
tional file 2). PCR was performed on bisulfite treated
DNA using the following reaction conditions, 1 cycle:
95°C for 3 min, 55 cycles: 95°C for 1 min followed by
56.8°C for 1 min followed by 72°C for 3 min, and a final
extension at 72°C for 5 min. The reaction was run on an
agarose gel and the bands were gel extracted (Qiagen,
Valencia, CA, USA) and TOPO TA cloned (Invitrogen,
Carlsbad, CA, USA). Single clones were isolated and plas-
mids purified (Qiagen, Valencia, CA, USA). Sequencing
was performed using the M13 forward primer provided
with the TOPO TA cloning kit. On average, 10 individual
clones were sequenced per amplicon in order to calculate
percentage methylation at each of the CpG sites (note: 8
clones were used in OXTR family analysis). Bisulfite con-
version was verified for each clone by assessing the C to T
conversion of non-CpG sites. The average methylation
level (%) was determined for each individual and these
values were used to generate an average percentage meth-
ylation for each group, autism cases and normal controls,
respectively (Additional file 1). The Welch-Satterthwaite t
test was employed to adjust for unequal variances
between groups and to compare the mean methylation
level (%) at each site between the autism cases versus con-
trol groups. A nominal significance of P ≤ 0.05 indicated
a significant change in the methylation state between the
two groups. The direction of the change was determined
by comparing the average methylation level at each site
between the two groups.BMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
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Expression analysis by quantitative PCR (qPCR)
Total RNA was extracted from four case-control pairs
matched for age, sex and PMI (see Table 1) using the TRI-
zol reagent (Invitrogen, Carlsbad, CA, USA) according to
standard methods, and RNA quality was checked using a
Bioanalyzer (Agilent, Santa Clara, CA, USA). Reverse tran-
scription was performed with the QuantiTect Reverse
Transcription kit (Qiagen, Valencia, CA, USA), using ran-
dom hexamers as primers and a starting RNA quantity of
1 μg in a 20 μl final volume. OXTR cDNA was quantified
using an iQ5 Multicolour Real-time PCR Apparatus (Bio-
Rad, Hercules, CA, USA), according to a standard ΔΔCt
Syber Green protocol [43]. PPIA  (MIM accession no.:
123840) cDNA was measured in parallel and used as a
standard for normalization. Due to relatively low neocor-
tical OXTR gene expression levels compared to PPIA, PCR
reactions were performed using 1:5 and 1:25 cDNA dilu-
tions, respectively. OXTR primers were targeted to exon 2,
which is shared by all four alternative mRNA transcripts,
and designed as follows: F2, 5'-CTGAACATCCCGAG-
GAACTG-3', and R2, 5'-CTCTGAGCCACTGCAAATGA-3'.
To ensure specificity, PCR products were initially
sequenced using a CEQ8000 DNA sequencer (Beckman-
Coulter, Fullerton, CA, USA), and afterwards checked by
running a melting curve at the end of each experiment.
Analysis was performed using the 2-ΔΔC
T method [41] and
expression level from the group of cases and the group of
controls were compared using a one-tailed paired t test.
Results
Normal-normal analysis
Array CGH data was generated for 54 phenotypically nor-
mal individuals in 27 sex-mismatched hybridizations to
establish the performance of our large insert bacterial
clones on the genomic tilepath microarray. Sex mismatch-
ing was used to establish the baseline of heterozygous loss
using the X chromosome as a reference. Analysis of the 27
normal-normal array CGH experiments identified 12
CNVs within 2 or more of the array CGH hybridizations.
In all, 10 CNVs were contained within previously pub-
lished CNVs from the database of genomic variants [28],
while 2 CNVs extended the size of the known CNV regions
(Additional file 3).
Autism CNVs
The genomic profiles of 119 idiopathic autism probands
(93 male and 26 female) were generated by sex-mismatch
array CGH experiments using controls from our normal-
normal analysis. A total of 113 loci within 111 autistic
individuals contained at least 1 genomic deletion or
duplication, with a range of 1-6 CNVs per individual
(Additional file 3). Approximately half of these, 52, were
wholly contained within known copy number variants
from the Database of Genomic Variants [28], 57 loci over-
lapped with 1 or more known CNVs regardless of size
(CNV regions), and 5 were novel regions of loss (n = 2) or
gain (n = 3) that contained 21 genes (Additional file 3).
According to Fable http://fable.chop.edu/ only one gene
within these novel regions, ring finger protein 19A
(RNF19A, also known as p38) in a 0.6 Mb deletion on
chromosome 8q22.2, has been previously implicated in
autism spectrum disorders (ASDs) via an observation in
Rett syndrome [44], and none fell within previous regions
of linkage (as reviewed in [7]). We chose to focus on 19 of
the 113 putative deletions or duplications identified in
the first screen to validate by array CGH dye swap experi-
ments using select individuals (Additional file 3, top) or,
in the case of the OXTR deletion described below, by mic-
rosatellite and quantitative real-time PCR analysis.
Genomic rearrangements of note included a 12.5 Mb
deletion within 2q24.1-2q24.3, a region previously linked
to autism [45,46] and containing 41 known genes; a 4.6
Mb duplication and a 3.4 Mb deletion within 15q11-13
that contains a complex arrangement of CNVs and has
previously been associated with autism by numerous
genetic linkage [47-49] and genome copy number studies
[12-23]; and a 0.7 Mb deletion in 3p25.3 that contains 5
genes: Lim and cysteine-rich domains 1, LMCD1 (MIM
accession no.: 604859); C3orf32; Caveolin 3, CAV3 (MIM
accession no.: 601253); oxytocin receptor, OXTR (MIM
accession no.: 167055); and RAD18 (MIM accession no.:
605256) (Figure 1). Though this region contains known
smaller copy number variants, none of these correspond
to a deletion of 0.7 Mb identified by this study or contain
the genes mentioned above. Additionally, OXTR is a can-
didate autism gene whose levels may be important for
social development of offspring [50].
Copy number analysis of OXTR
Based on the strength of the novel deletion of OXTR and
the previous data implicating OXTR in the development
of autism [51-53], we focused further copy number anal-
ysis on the 3p25.3 deletion by screening other members
of the proband's family. Quantitative real-time PCR (qRT-
PCR) analysis confirmed that the deletion containing
OXTR was not a de novo event (Figure 2a) and microsatel-
lite analysis confirmed that the deletion was inherited
from the mother (Figure 2b), who has possible OCD (not
clinically evaluated). OCD cases have been reported to be
more common among first-degree relatives of autistic
probands, which may hint at a common genetic mecha-
nism or pathway shared between these two disorders
[54,55]. Curiously, the proband's affected brother did not
inherit the allele containing the genomic deletion (Figure
2). Microsatellite analysis of the deletion revealed that the
proband's alternative allele was inherited from the father,
therefore excluding the prospect of uniparental disomy at
the OXTR locus contributing to the phenotype (Figure 2).
Methylation analysis of the OXTR promoter region
Based on the CNV data within the OXTR deletion family,
we hypothesized that a hemizygous deletion of OXTRBMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
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may result in a reduction in the available levels of OXTR
in utero and during development, ultimately leading to the
development of autism. However, if this is true, it is
unclear how this deletion confers autism in the proband
when the proband's affected sibling does not carry the
deletion. To investigate the possibility that a mechanism
other than a genomic deletion may play a role in decreas-
ing OXTR levels in the affected sibling we investigated the
DNA methylation status, a form of epigenetic silencing, of
two regions of OXTR previously shown to be methylated
and associated with differential expression of the gene in
liver and myometrium [56,57]. We carried out bisulfite
sequencing (BSS) analysis of cloned alleles of two OXTR
CpG islands in the peripheral blood mononuclear cells
(PBMCs) of all four family members (Figure 3). The first
CpG island overlaps exons 1, 2, and 3 of OXTR and is
located on chromosome 3 at 8,783,962-8,786,280 base
pairs (Ensembl Homo sapiens version 54.36p, NCBI36).
Kusui et al. had shown that the methylation status of a
specific 405 base-pair fragment of this CpG island
(termed 'MT2' by Kusui et al.) is important for tissue-spe-
cific expression of OXTR (Figure 3 depicts MT2 position).
The second CpG island is located within the third intron
of OXTR on chromosome 3 at 8,775,160-8,776,624 base
pairs (Ensembl Homo sapiens version 54.36p, NCBI36).
This island has previously been experimentally defined as
an EcoRI-KpnI fragment that was less methylated in myo-
metrial DNA than in the DNA from peripheral blood leu-
kocytes [42]. All CpG dinucleotides tested within the
intron 3 CpG island were heavily methylated in all family
members (data not shown). However, several of the 33
CpG dinucleotides tested within the region overlapping
exons 1, 2, and 3 of OXTR differed in methylation level
between family members. Specifically, CpG dinucleotides
at positions -959, -934, -924, -901 and -860 (relative to
translation start site) showed the most dramatic differ-
ences in methylation status, with the proband's affected
sibling being heavily methylated at sites -934, -924 and -
901. These specific residues fall within the critical region
(MT2) in the CpG island of OXTR shown by Kusui et al. to
Graphical representation of the 0.7 Mb heterozygous deletion in 3p25.3 (8,231,927-8,985,513 base pairs) within an individual  with autism identified by array comparative genomic hybridization (CGH) Figure 1
Graphical representation of the 0.7 Mb heterozygous deletion in 3p25.3 (8,231,927-8,985,513 base pairs) within 
an individual with autism identified by array comparative genomic hybridization (CGH). The horizontal ideogram 
represents the chromosome 3 region of interest with the log2 plot below it of array CGH results from the tilepath clones (indi-
vidual blue circles) on the genomic array. The dotted line at '0' represents copy neutral log2 plot between the cohybridized 
samples, while the green line represents single copy gain and the red line single copy loss. OXTR and four adjacent genes are 
contained within a deletion called in Nexus by circular binary segmentation (CBS) [40] (bold black line). Known copy number 
variants from the Database of Genomic Variants http://projects.tcag.ca/variation/ are denoted by horizontal pink bars.BMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
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regulate the expression of OXTR in liver [56]. Importantly,
in keeping with the hypothesis that increases in DNA
methylation (hypermethylation) lead to gene silencing,
CpG sites -934 and -924 showed the largest increase in
methylation, 37.5%, between the autistic sibling and the
non-autistic father (62.5% methylated versus 25% meth-
ylated, 100% methylated versus 62.5% methylated,
respectively), both lacking the OXTR deletion. The 100%
methylation of a specific CpG could indicate maintenance
of an aberrant methylation mark, making this a more dra-
matic change.
Hypermethylation of residues critical for OXTR gene 
silencing are associated with autism
Given the data observed within the OXTR deletion family,
we hypothesized that DNA methylation of residues found
within the critical region of OXTR regulation may extend
beyond this family and represent a more general epige-
netic contribution to autism spectrum disorders. We
extended our BSS analysis of the 5 differentiallly methyl-
ated CpG dinucleotides to PBMCs from 20 phenotypically
normal control individuals (10 males and 10 females)
and 20 individuals with autism (10 males and 10
females). BSS data showed significantly increased methyl-
ation in the PBMCs of CpG -860 (P = 0.0009), -934 (P =
0.0081) and -959 (P = 0.0026) in individuals with autism
compared to controls (Table 2). When the data are strati-
fied by sex, the associated significance of -860 and -934
can be ascribed only to males (Table 3) and that of -959
to females (Additional file 4).
Hypermethylation of OXTR CpG sites in temporal cortex 
tissue of autistic individuals
To determine if differential methylation of the five puta-
tive regulatory OXTR CpG dinucleotides may be impor-
tant in a tissue implicated in the etiology of autism, we
analyzed temporal cortex tissue from eight individuals
with autism and eight controls matched for age and sex
(see clinical data in Table 1), six male and two female. The
BSS results in the cortex again showed statistically signifi-
cant hypermethylation in the autism cases versus normal
controls. There was significant increased methylation at
CpG -860 (P = 0.0251), CpG -901 (P = 0.0149), CpG -924
(P = 0.0448) and CpG -934 (P = 0.0233) between autism
cortex tissue compared to the normal cortex controls
(Additional file 5). We performed a stratified analysis to
increase the homogeneity within the sample using six
male samples matched for age and sex, and to validate our
sex-specific findings in blood. This analysis reproduced
the significance at sites -924 and -934 (Table 3).
Microsatellite and quantitative real-time polymerase chain reaction (PCR) validation of OXTR deletion Figure 2
Microsatellite and quantitative real-time polymerase chain reaction (PCR) validation of OXTR deletion. (a) 
Microsatellite markers within and adjacent to the copy variable region in the OXTR deletion family were assayed to confirm 
homozygosity and parental transfer of alleles. (b) Normalized real-time PCR results confirm the loss of a single copy of OXTR 
in both the mother and the proband (marked by a black triangle). Copy number was normalized to RNAseP and controls were 
used to verify deletion. The 1 × control is a tumor sample with a known chromosome 3 deletion. The 2 × control is an unaf-
fected sample from the copy number variant (CNV) study in this paper that is not copy variable at OXTR.
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Expression analysis of OXTR in temporal cortex tissue of 
OXTR
To functionally correlate DNA methylation levels within
the temporal cortex DNA and expression of OXTR from
which the DNA was derived, we carried out quantitative
PCR analysis of mRNA levels from the cortex tissue of four
autism cases matched for age and sex and four controls.
Assays were designed to exon 2 of the gene. Although
OXTR expression levels were low, we detected a sex-spe-
cific decrease in expression of OXTR for each of the autis-
tic male control pairs tested (Figure 4a), and in two of the
three cases expression levels correlated with an increase in
methylation at site -934. As a group, autistic males
showed a 20% decrease in expression compared to con-
trols that was significant at P = 0.0389 (Figure 4b). These
data suggest that increased methylation of the promoter
in OXTR correlates with decreased expression of the gene
in a tissue type relevant to the development of autism.
Discussion
For several years the characterization of CNVs in autism
patients has identified genes that potentially contribute to
the etiology of the disorder [9,58-60]. In this study we
used high-resolution genomic tilepath arrays with com-
CpG dinucleotides analyzed within a predicted CpG island in the promoter region of OXTR Figure 3
CpG dinucleotides analyzed within a predicted CpG island in the promoter region of OXTR. Untranslated regions 
are represented as gray boxes and protein coding exons are white boxes, the site of translation is denoted by a black arrow. 
Predicted CpG islands are horizontal black bars beneath the gene. The region of interest within the 5' CpG island, MT2 as 
reported by Kusui et al. [56], is denoted by a dashed line (NCBI36 coordinates). Groups of CpGs sequenced per clone are indi-
cated with brackets. Clear circles with diagonal lines denote untested CpG dinucleotides, filled circles represent region of 
interest. CpGs of interest are numbered according to translation initiation site of +1. Clear boxes denote CpG dinucleotides 
that showed no methylation in bisulfite sequencing of subclones; black within boxes denotes methylation of the CpG dinucle-
otide; F = Father, M = Mother, P = Proband, S = Sibling.
-
OXTR
CpG island
Ͳ959
Ͳ934
Ͳ924 Ͳ860
Ͳ901
Chromosome 3 MT2
8 785 719
￿
￿
8 786 124 bp
F
M
8,785,719
￿
￿
8,786,124 bp
P
M
S
Table 2: OXTR promoter CpG methylation levels in peripheral blood mononuclear cells
Site AutD cases (95% CI), (n = 20) Controls (95% CI), (n = 20) t Test
-860 35.1% (22.6 to 46.7) 12.2% (6.5 to 17.9) 0.0009
-901 52.0% (42.4 to 61.6) 45.2% (32.5 to 57.8) 0.3761
-924 68.1% (58.2 to 78.0) 65.8% (54.4 to 77.3) 0.7558
-934 56.4% (43.4 to 69.4) 33.4% (22.2 to 44.6) 0.0081
-959 50.9% (42.4 to 59.4) 32.0% (23.2 to 40.8) 0.0026
Bold text indicates a significant result by Satterthwaite test; % = percentage methylated.
CI = confidence interval; AutD = autism disorder.BMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
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parative genomic hybridization to identify 113 CNVs
within 119 unrelated autistic individuals. Of note were
five novel CNVs that do not map to prior regions of link-
age and which, according to Fable http://fable.chop.edu/,
contain only one gene in 8q22.2 (RNF19A) that has pre-
viously been implicated in autism spectrum disorders
[44]. CNVs observed in known autism regions included a
12.5 Mb deletion within 2q24.1-2q24.3 [45,46], two rear-
rangements in 15q11-13 [12-23,47-49], and a 0.7 Mb
deletion in 3p25.3. We chose to focus on the deletion in
chromosome 3p25.3 because of previous reported linkage
to the region [61,62], association data implicating the
oxytocin receptor (OXTR) that is contained within the
deletion to the etiology of autism [51-53]. More recently,
the DECIPHER database https://decipher.sanger.ac.uk/
has had copy number data deposited from a syndromic
patient who has developmental delay and cognitive
impairment presumably emanating from a novel 1.1 Mb
deletion that contains OXTR, amongst other genes.
Detailed DNA methylation analysis of the promoter
region of OXTR, prompted by the observation that the
proband's autistic brother did not carry the novel dele-
tion, identified a single CpG dinucleotide within a known
OXTR control region [56] that, independently, showed a
statistically significant increase in methylation in PBMCs
and the temporal cortex tissue of autism cases compared
to controls. The identification of similar methylation pro-
files in the temporal cortex and peripheral blood may be
indicative of an early developmental event during which
these profiles are differentially established, prior to germ
layer specification. If this locus is epigenetically labile,
then it might be vulnerable to (unknown) exposures in
utero during the first few weeks of pregnancy that lead to
shifts in methylation status of OXTR. Similar influences
have been seen in IGF2 methylation based on in utero
exposures such as smoking and folic acid intake in
humans [63]. Since epigenetic profiles undergo repro-
gramming during very early gestation (fertilization to
implantation), it is not surprising that the profiles in these
two disparate tissue types of ectodermal and mesodermal
origin are similar and furthermore provides a potential
means for detection in multiple, more accessible tissues.
The impact of this epigenetic mark on OXTR expression
was supported by analysis of the corresponding mRNA
from the temporal cortex of autism cases matched for age
and sex and controls. As one would hypothesize given
their increased methylation of OXTR, the autism cases
also showed statistically lower transcript levels of OXTR
expression compared to the normal controls. Because
deletions encompassing OXTR have not been observed in
other studies characterizing structural variation in autism
[58,64,65] such events appear to be rare. At the same time
our findings suggest that the hypermethylated status of
OXTR in autism, resulting in a decrease in OXTR expres-
sion, may more commonly contribute to the disorder.
While the mechanism for the development of autism
from a germ line deletion of OXTR  versus epigenetic
silencing of the gene in the temporal cortex may clearly be
different, the effect on oxytocin signaling could be the
same. Together, these data provide strong evidence for the
role of OXTR and oxytocin signaling pathway in the etiol-
ogy of autism and, for the first time, show that the epige-
netic regulation of OXTR may be an important factor in
the development of the disorder.
Epigenetic control of autism susceptibility is a recent con-
cept and most certainly a topic of great interest in the field.
Over the past decade, researchers have uncovered sugges-
tive links between epigenetics and autism, for example,
autism is associated with duplications of 15q11-13 (espe-
cially maternally inherited), an imprinted region in the
genome where DNA methylation status has been linked
to Prader-Willi syndrome (PWS) and Angelman syn-
drome (AS) [66]; mutation within a gene that encodes a
methyl-DNA-binding protein (MECP2, (MIM accession
no.: 300005)) is the causative agent of Rett syndrome
[67]; and mutation of this same gene has been associated
Table 3: OXTR promoter CpG methylation status in peripheral blood mononuclear cells (PBMCs) and cortex samples of males
Site AutD cases (95%CI), (n = 10) Controls (95%CI), (n = 10) t Test
PBMCs:
-860 41.0% (28.4 to 53.7) 13.8% (6.6 to 21.0) 0.0008
-901 48.1% (33.6 to 62.7) 36.9% (19.1 to 54.7) 0.3153
-924 71.1% (59.4 to 82.8) 59.3% (40.8 to 77.8) 0.2604
-934 58.7% (39.4 to 78.1) 19.8% (3.2 to 36.4) 0.0029
-959 48.6% (39.5 to 57.6) 41.7% (27.5 to 55.9) 0.3522
Cortex:
-860 38.8% (5.4 to 72.2) 14.9% (3.6 to 26.2) 0.1208
-901 47.1% (13.1 to 81.2) 13.3% (3.6 to 23.0) 0.0508
-924 64.3% (30.6 to 98.0) 26.6% (7.2 to 46.1) 0.0375
-934 61.0% (24.4 to 97.5) 19.4% (1.1 to 37.7) 0.0320
-959 20.5% (8.0 to 32.9) 19.4% (1.1 to 37.7) 0.9032
Bold text indicates a significant result by Satterthwaite test; %, percentage methylated. Cases and controls were all male.
CI = confidence interval; AutD = autism disorder.BMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
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with both autism and AS populations [55]. Nagarajan et al
have shown that 79% of autism cases have a decrease in
MECP2  expression in the frontal cortex and that an
increase in aberrant DNA methylation correlates with this
decrease in MECP2 expression [68]. These data implicate
epigenetic dysregulation as a mechanism for the develop-
ment of autism and justify the examination of DNA meth-
ylation of autism candidate genes, such as OXTR
identified in this study.
The oxytocin receptor, OXTR, is spatially and temporally
regulated by a complex combination of sex hormones,
inflammatory cytokines, oxytocin (OXT) feedback and
epigenetic mechanisms [56,57]. It is a high affinity G-pro-
tein coupled receptor for OXT, a nine amino acid hor-
mone that has important and complex roles in animal
physiology and behavior [69], including parturition and
neurotransmission. A putative role for OXT in the devel-
opment of ASDs was first highlighted by Insel and col-
leagues [70] who showed that signaling of oxytocin and
the closely related molecule vasopressin play important
'prosocial' roles influencing social behavior and cognitive
function in a species-specific manner [71-73]. Subsequent
studies in mice revealed that Oxt  [74] and Oxtr  [75]
knockouts largely resulted in normal parturition, how-
ever, social memory was impaired. Recently, Lee and col-
leagues [76] showed that only male mice with a targeted
forebrain knock out of Oxtr exhibited social impairment
by failure to recognize individuals of their own species. It
has been suggested that the normal social behavior of the
female knockout mice may be attributed to the compen-
satory function of vasopressin or developmental compen-
sation [69,77]. In an excellent review by Carter [50] that
describes the complex sexually dimorphic roles of vaso-
pressin and oxytocin in brain function and behavior, it is
apparent that aberrant oxytocin and/or vasopressin sign-
aling is likely to elicit sex-specific outcomes, which is of
particular relevance to autism because of disproportionate
number of affected males. Our family analysis identified
an OXTR deletion in the mother who does not present
with autism. Sex-specific effects of OXTR function from
animal models, together with statistical data that suggest
dominantly acting de novo mutations may have reduced
penetrance in females [78], may explain why the hetero-
zygous deletion of OXTR in the mother from our study
does not result in autism while the male proband displays
the disorder.
We identified a single CpG dinucleotide within a pre-
dicted CpG island that showed statistically significant
hypermethylation in PBMCs and the temporal cortex of
individuals with autism compared to controls. Although
the dominant paradigm for regulation of transcription by
DNA methylation suggests that clusters of CpGs are neces-
sary for silencing, recent evidence has indicated that meth-
ylation of single CpG dinucleotides may also lead to
transcriptional changes via interference of transcription
factor binding or recruitment of silencing factors [79].
This is the most likely explanation for the findings pre-
sented here as CpG site -934 falls within a predicted c-Rel,
ZHX2, and LGALS4 binding domains (T. Wang, personal
communication). However, further molecular work is
required to dissect the likely complex transcriptional reg-
ulation of OXTR.
In this study, we focused on the temporal cortex (Brod-
mann areas 41/42 and 22) because studies have shown
that localized temporal dysfunction is linked with clinical
symptoms in autism, such as perceptive, emotional and
cognitive deficits [32-35]. Although we were not able to
determine the methylation status of cortex tissue from the
family in which we observed the OXTR deletion, the data
we collected from the affected sibling shows hypermethyl-
ation of the CpG dinucleotide (-934) in the predicted
CpG island upstream of OXTR. Given our results suggest-
Expression of OXTR in the cortex of male autistic brains is  decreased compared to controls Figure 4
Expression of OXTR in the cortex of male autistic 
brains is decreased compared to controls. OXTR 
expression in the cortex was quantitated using quantitative 
real-time polymerase chain reaction (qRT-PCR) and normal-
ized to PPIA in four cases (autism) and controls matched for 
age and sex. (a) The expression level of OXTR is decreased 
in male cases compared to controls and the methylation of 
site -934 (Me-CpG) correlates with expression in two of the 
male individuals. (b) As a group, the expression of OXTR in 
the cortex of the male autistic brain is significantly lower than 
in controls matched for age and sex. †Paired t test.
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ing that DNA methylation of OXTR in PBMCs may be a
marker of methylation status in the temporal cortex, it fol-
lows that the affected sibling may also exhibit a decrease
in OXTR expression due to methylation instead of dele-
tion; thus implicating two separate mechanisms of tran-
scriptional regulation with the same outcome. These
results suggest that because the methylation status of site
-934 is significantly different in the temporal cortex and
PBMCs between autism cases and controls, measuring the
methylation status of OXTR from the blood for autism
cases could act as a surrogate for methylation status in the
temporal cortex and be diagnostic of affection status,
together with traditional diagnostic criteria.
Conclusion
In summary, the data presented suggest that genomic
deletion or aberrant methylation of OXTR may contribute
to the development of autism. We acknowledge that
screening for these genomic changes in a large, well con-
trolled autism sample is necessary to determine the prev-
alence of these changes and their relationship to the
disease. However, regardless of the sample size, we pro-
vide strong evidence that the epigenetic regulation of
OXTR may be an important factor in the development of
the disorder and suggest that further studies begin to focus
on this regulatory event and its relationship to disease.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SGG conceived the experimental design and wrote the
paper; JJC assisted with experimental design, carried out
experiments and wrote the paper; AT, JJ, DB, DB, CM and
CL carried out the experiments; RKA, HHW, GW ascer-
tained autism families for the paper; PE and CFL assisted
with experimental design, SKM assisted with the writing
of the paper; MLC helped ascertain autism families and
assisted with clinical assessment of the study population;
AP and MAP-V assisted with experimental design and in
the writing of the paper.
Additional material
Acknowledgements
We thank all the patients and families who generously participated in this 
study, including the donors and their families of the cortex tissue, and the 
collaborating clinics and physicians for referring individuals to the study. 
We would also like to thank Joshua Virgadamo, Christina Sheedy and 
Rachel Cote for their laboratory assistance, Dr Elizabeth Hauser for evalu-
ating our statistical techniques, Dr Ty Wang for transcription factor binding 
analysis, and Sarah Nelson for comments on the draft of this manuscript. 
This research was supported by the JP Hussman Foundation and National 
Institutes of Health grants P01-NS026630 and R01-NIH080647, and by 
MIUR PRIN 2006058195 (AMP). We also gratefully acknowledge the 
Autism Tissue Program, the Maryland NICHD Brain Tissue Center and the 
Harvard Brain Tissue Resource Center for providing brain tissues for this 
study (SGG and AMP).
References
1. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C,
Murphy C: Prevalence of autism in a US metropolitan area.
JAMA 2003, 289:49-55.
2. Volkmar FR, Szatmari P, Sparrow SS: Sex differences in pervasive
developmental disorders.  J Autism Dev Disord 1993, 23:579-591.
3. McLennan JD, Lord C, Schopler E: Sex differences in higher func-
tioning people with autism.  J Autism Dev Disord 1993, 23:217-227.
4. Muhle R, Trentacoste SV, Rapin I: The genetics of autism.  Pediat-
rics 2004, 113:e472-e486.
5. Gutierrez GC, Smalley SL, Tanguay PE: Autism in tuberous scle-
rosis complex.  J Autism Dev Disord 1998, 28:97-103.
6. Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A,
Cuccaro ML, Vance JM, Pericak-Vance MA: Identification of
MeCP2 mutations in a series of females with autistic disor-
der.  Pediatr Neurol 2003, 28:205-211.
7. Abrahams BS, Geschwind DH: Advances in autism genetics: on
the threshold of a new neurobiology.  Nat Rev Genet 2008,
9:341-355.
8. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS,
Salyakina D, Imielinski M, Bradfield JP, Sleiman PM, Kim CE, Hou C,
Frackelton E, Chiavacci R, Takahashi N, Sakurai T, Rappaport E,
Lajonchere CM, Munson J, Estes A, Korvatska O, Piven J, Sonnenblick
LI, Alvarez Retuerto AI, Herman EI, Dong H, Hutman T, Sigman M,
Ozonoff S, Klin A: Common genetic variants on 5p14.1 associ-
ate with autism spectrum disorders.  Nature 2009, 459:528-533.
Additional file 1
Cloned bisulfite sequencing results for each peripheral blood mononu-
clear cell (PBMC) sample.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-62-S1.XLS]
Additional file 2
Primer pairs used for this study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-62-S2.XLS]
Additional file 3
Genomic duplication and deletion events within 54 control and 119 
autistic individuals identified by whole genome tilepath array compar-
ative genomic hybridization (CGH).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-62-S3.XLS]
Additional file 4
OXTR promoter CpG methylation status in peripheral blood mononu-
clear cells (PBMCs) of 10 autistic females and 10 age-matched con-
trols.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-62-S4.XLS]
Additional file 5
OXTR promoter CpG methylation status in the cortex of eight autism 
cases and controls matched for age and sex.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-7-62-S5.XLS]BMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
Page 12 of 13
(page number not for citation purposes)
9. Folstein SE, Rosen-Sheidley B: Genetics of autism: complex aeti-
ology for a heterogeneous disorder.  Nat Rev Genet 2001,
2:943-955.
10. Gillberg C: Chromosomal disorders and autism.  J Autism Dev
Disord 1998, 28:415-425.
11. Lauritsen M, Mors O, Mortensen PB, Ewald H: Infantile autism and
associated autosomal chromosome abnormalities: a regis-
ter-based study and a literature survey.  J Child Psychol Psychiat
1999, 4:335-345.
12. Baker P, Piven J, Schwartz S, Patil S: Brief report: duplication of
chromosome 15q11-13 in two individuals with autistic disor-
der.  J Autism Dev Disord 1994, 24:529-535.
13. Bundey S, Hardy C, Vickers S, Kilpatrick MW, Corbett JA: Brief
report: duplication of chromosome 15q11-13 in two individ-
uals with autistic disorder.  Dev Med Child Neurol 1994,
36:736-742.
14. Hotopf M, Bolton P: A case of autism associated with partial
tetrasomy 15.  J Autism Dev Disord 1995, 25:41-49.
15. Flejter WL, Bennett-Baker PE, Ghaziuddin M, McDonald M, Sheldon
S, Gorski JL: Cytogenetic and molecular analysis of inv dup(15)
chromosomes observed in two patients with autistic disor-
der and mental retardation.  Am J Med Genet 1996, 61:182-187.
16. Cook EH Jr, Lindgren V, Leventhal BL, Courchesne R, Lincoln A, Shul-
man C, Lord C, Courchesne E: Autism or atypical autism in
maternally but not paternally derived proximal 15q duplica-
tion.  Am J Hum Genet 1997, 60:928-934.
17. Repetto GM, White LM, Bader PJ, Johnson D, Knoll JH: Interstitial
duplications of chromosome region 15q11q13: Clinical and
molecular characterization.  Am J Med Genet 1998, 79:82-89.
18. Schroer RJ, Phelan MC, Michaelis RC, Crawford EC, Skinner SA, Cuc-
caro M, Simensen RJ, Bishop J, Skinner C, Fender D, Stevenson RE:
Autism and maternally derived aberrations of chromosome
15q.  Am J Med Genet 1998, 76:327-336.
19. Gurrieri F, Battaglia A, Torrisi L, Tancredi R, Cavallaro C, Sangiorgi E,
Neri G: Pervasive developmental disorder and epilepsy due
to maternally derived duplication of 15q11-q13.  Neurology
1999, 52:1694-1697.
20. Buoni S, Sorrentino L, Farnetani MA, Pucci L, Fois A: The syndrome
of inv dup (15): clinical, electroencephalographic, imaging
findings.  J Child Neurol 2000, 15:380-385.
21. Boyar FZ, Whitney MM, Lossie AC, Gray BA, Keller KL, Stalker HJ,
Zori RT, Geffken G, Mutch J, Edge PJ, Voeller KS, Williams CA, Dris-
coll DJ: A family with a grand-maternally derived interstitial
duplication of proximal 15q.  Clin Genet 2001, 60:421-430.
22. Silva AE, Vayego-Lourenco SA, Fett-Conte AC, Goloni-Bertollo EM,
Varella-Garcia M: Tetrasomy 15q11-q13 identified by fluores-
cence in situ hybridization in a patient with autistic disorder.
Arq Neuropsiquiatr 2002, 60:290-294.
23. Filipek PA, Juranek J, Smith M, Mays LZ, Ramos ER, Bocian M, Masser-
Frye D, Laulhere TM, Modahl C, Spence MA, Gargus JJ: Mitochon-
drial dysfunction in autistic patients with 15q inverted dupli-
cation.  Ann Neurol 2003, 53:801-804.
24. Rineer S, Finucane B, Simon EW: Autistic symptoms among chil-
dren and young adults with isodicentric chromosome 15.  Am
J Med Genet 1998, 81:428-433.
25. Thomas JA, Johnson J, Peterson Kraai TL, Wilson R, Tartaglia N, LeR-
oux J, Beischel L, McGavran L, Hagerman RJ: Genetic and clinical
characterization of patients with an interstitial duplication
15q11-q13, emphasizing behavioral phenotype and response
to treatment.  Am J Med Genet A 2003, 119:111-120.
26. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S,
Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K,
Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M:
Large-scale copy number polymorphism in the human
genome.  Science 2004, 305:525-528.
27. Cuccaro ML, Shao Y, Bass MP, Abramson RK, Ravan SA, Wright HH,
Wolpert CM, Donnelly SL, Pericak-Vance MA: Behavioral compar-
isons in autistic individuals from multiplex and singleton
families.  J Autism Dev Disord 2003, 33:87-91.
28. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y,
Scherer SW, Lee C: Detection of large-scale variation in the
human genome.  Nat Genet 2004, 36:949-951.
29. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview-
Revised: a revised version of a diagnostic interview for car-
egivers of individuals with possible pervasive developmental
disorders.  J Autism Dev Disord 1994, 24:659-685.
30. Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S, Fom-
bonne E, Leboyer M, Minshew N: Diagnosing autism: analyses of
data from the Autism Diagnostic Interview.  J Autism Dev Disord
1997, 27:501-517.
31. Vance JM: The collection of biological samples for DNA anal-
ysis.  I n  Approaches to Gene Mapping in Complex Human Diseases
Edited by: Haines JL, Pericak-Vance MA. New York, USA: Wiley-Liss;
1998. 
32. Ohnishi T, Matsuda H, Hashimoto T, Kunihiro T, Nishikawa M, Uema
T, Sasaki M: Abnormal regional cerebral blood flow in child-
hood autism.  Brain 2000, 123:1838-1844.
33. Lee JE, Bigler ED, Alexander AL, Lazar M, DuBray MB, Chung MK,
Johnson M, Morgan J, Miller JN, McMahon WM, Lu J, Jeong EK, Lain-
hart JE: Diffusion tensor imaging of white matter in the supe-
rior temporal gyrus and temporal stem in autism.  Neurosci
Lett 2007, 424:127-132.
34. Boddaert N, Belin P, Chabane N, Poline JB, Barthelemy C, Mouren-
Simeoni MC, Brunelle F, Samson Y, Zilbovicius M: Perception of
complex sounds: abnormal pattern of cortical activation in
autism.  Am J Psychiatry 2003, 160:2057-2060.
35. Zilbovicius M, Boddaert N, Belin P, Poline JB, Remy P, Mangin JF, Thi-
vard L, Barthelemy C, Samson Y: Temporal lobe dysfunction in
childhood autism: a PET study. Positron emission tomogra-
phy.  Am J Psychiatry 2000, 157:1988-1993.
36. Campbell DB, D'Oronzio R, Garbett K, Ebert PJ, Mirnics K, Levitt P,
Persico AM: Disruption of cerebral cortex MET signaling in
autism spectrum disorder.  Ann Neurol 2007, 62:243-250.
37. Lintas C, Sacco R, Garbett K, Mirnics K, Militerni R, Bravaccio C,
Curatolo P, Manzi B, Schneider C, Melmed R, Elia M, Pascucci T,
Puglisi-Allegra S, Reichelt KL, Persico AM: Involvement of the
PRKCB1 gene in autistic disorder: significant genetic associ-
ation and reduced neocortical gene expression.  Mol Psychiatry
2009, 14:705-718.
38. Siegel B: Toward DSM-IV: a developmental approach to autis-
tic disorder.  Psychiatr Clin North Am 1991, 14:53-68.
39. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Smith J, Vetrie D,
Gorman P, Tomlinson IP, Carter NP: DNA microarrays for com-
parative genomic hybridization based on DOP-PCR amplifi-
cation of BAC and PAC clones.  Genes Chromosomes Cancer 2003,
36:361-374.
40. Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary
segmentation for the analysis of array-based DNA copy
number data.  Biostatistics 2004, 5:557-572.
41. Livak KJ, Schmittgen TD: Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-ΔΔC(T))
method.  Methods 2001, 25:402-408.
42. Mizumoto Y, Kimura T, Ivell R: A genomic element within the
third intron of the human oxytocin receptor gene may be
involved in transcriptional suppression.  Mol Cell Endocrinol
1997, 135:129-138.
43. Bustin SA: Absolute quantification of mRNA using real-time
reverse transcription polymerase chain reaction assays.  J Mol
Endocrinol 2000, 25:169-193.
44. Belichenko PV, Hagberg B, Dahlstrom A: Morphological study of
neocortical areas in Rett syndrome.  Acta Neuropathol 1997,
93:50-61.
45. International Molecular Genetic Study of Autism Consortium: A full
genome screen for autism with evidence for linkage to a
region on chromosome 7q.  Hum Mol Genet 1998, 7:571-578.
46. Philippe A, Martinez M, Guilloud-Bataille M, Gillberg C, Rastam M,
Sponheim E, Coleman M, Zappella M, Aschauer H, Van Maldergem L,
P e n e t  C ,  F e i n g o l d  J ,  B r i c e  A ,  L e b o y e r  M ,  v a n  M a l l d e r g e r m e  L :
Genome-wide scan for autism susceptibility genes. Paris
Autism Research International Sibpair Study.  Hum Mol Genet
1999, 8:805-812.
47. Cook EH Jr, Courchesne RY, Cox NJ, Lord C, Gonen D, Guter SJ,
Lincoln A, Nix K, Haas R, Leventhal BL, Courchesne E: Linkage-dis-
equilibrium mapping of autistic disorder, with 15q11-13
markers.  Am J Hum Genet 1998, 62:1077-1083.
48. Nurmi EL, Bradford Y, Chen Y, Hall J, Arnone B, Gardiner MB, Hutch-
eson HB, Gilbert JR, Pericak-Vance MA, Copeland-Yates SA, Michae-
lis RC, Wassink TH, Santangelo SL, Sheffield VC, Piven J, Folstein SE,
Haines JL, Sutcliffe JS: Linkage disequilibrium at the Angelman
syndrome gene UBE3A in autism families.  Genomics 2001,
77:105-113.
49. Shao Y, Cuccaro ML, Hauser ER, Raiford KL, Menold MM, Wolpert
CM, Ravan SA, Elston L, Decena K, Donnelly SL, Abramson RK,
Wright HH, DeLong GR, Gilbert JR, Pericak-Vance MA: Fine map-
ping of autistic disorder to chromosome 15q11-q13 by use of
phenotypic subtypes.  Am J Hum Genet 2003, 72:539-548.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2009, 7:62 http://www.biomedcentral.com/1741-7015/7/62
Page 13 of 13
(page number not for citation purposes)
50. Carter CS: Sex differences in oxytocin and vasopressin: impli-
cations for autism spectrum disorders?  Behav Brain Res 2007,
176:170-186.
51. Wu S, Jia M, Ruan Y, Liu J, Guo Y, Shuang M, Gong X, Zhang Y, Yang
X, Zhang D: Positive association of the oxytocin receptor gene
(OXTR) with autism in the Chinese Han population.  Biol Psy-
chiatry 2005, 58:74-77.
52. Jacob S, Brune CW, Carter CS, Leventhal BL, Lord C, Cook EH Jr:
Association of the oxytocin receptor gene (OXTR) in Cauca-
sian children and adolescents with autism.  Neurosci Lett 2007,
417:6-9.
53. Lerer E, Levi S, Salomon S, Darvasi A, Yirmiya N, Ebstein RP: Asso-
ciation between the oxytocin receptor (OXTR) gene and
autism: relationship to Vineland Adaptive Behavior Scales
and cognition.  Mol Psychiatry 2008, 13:980-988.
54. Bolton PF, Pickles A, Murphy M, Rutter M: Autism, affective and
other psychiatric disorders: patterns of familial aggregation.
Psychol Med 1998, 28:385-395.
55. Micali N, Chakrabarti S, Fombonne E: The broad autism pheno-
type: findings from an epidemiological survey.  Autism 2004,
8:21-37.
56. Kusui C, Kimura T, Ogita K, Nakamura H, Matsumura Y, Koyama M,
Azuma C, Murata Y: DNA methylation of the human oxytocin
receptor gene promoter regulates tissue-specific gene sup-
pression.  Biochem Biophys Res Commun 2001, 289:681-686.
57. Kimura T, Saji F, Nishimori K, Ogita K, Nakamura H, Koyama M,
Murata Y: Molecular regulation of the oxytocin receptor in
peripheral organs.  J Mol Endocrinol 2003, 30:109-115.
58. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T,
Yamrom B, Yoon S, Krasnitz A, Kendall J, Leotta A, Pai D, Zhang R,
Lee YH, Hicks J, Spence SJ, Lee AT, Puura K, Lehtimaki T, Ledbetter
D, Gregersen PK, Bregman J, Sutcliffe JS, Jobanputra V, Chung W,
Warburton D, King MC, Skuse D, Geschwind DH, Gilliam TC, et al.:
Strong association of de novo copy number mutations with
autism.  Science 2007, 316:445-449.
59. Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu
XQ, Vincent JB, Skaug JL, Thompson AP, Senman L, Feuk L, Qian C,
Bryson SE, Jones MB, Marshall CR, Scherer SW, Vieland VJ, Bartlett
C, Mangin LV, Goedken R, Segre A, Pericak-Vance MA, Cuccaro ML,
Gilbert JR, Wright HH, Abramson RK, Betancur C, Bourgeron T, Gill-
berg C, Leboyer M, et al.: Mapping autism risk loci using genetic
linkage and chromosomal rearrangements.  Nat Genet 2007,
39:319-328.
60. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemu-
ndsen E, Stefansson H, Ferreira MA, Green T, Platt OS, Ruderfer DM,
Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, San-
tangelo SL, Gusella JF, Sklar P, Wu BL, Daly MJ: Association
between microdeletion and microduplication at 16p11.2 and
autism.  N Engl J Med 2008, 358:667-675.
61. McCauley JL, Li C, Jiang L, Olson LM, Crockett G, Gainer K, Folstein
SE, Haines JL, Sutcliffe JS: Genome-wide and ordered-subset
linkage analyses provide support for autism loci on 17q and
19p with evidence of phenotypic and interlocus genetic cor-
relates.  BMC Med Genet 2005, 6:1.
62. Ylisaukko-Oja T, Alarcon M, Cantor RM, Auranen M, Vanhala R,
Kempas E, von Wendt L, Jarvela I, Geschwind DH, Peltonen L:
Search for autism loci by combined analysis of Autism
Genetic Resource Exchange and Finnish families.  Ann Neurol
2006, 59:145-155.
63. Zeisel SH: Epigenetic mechanisms for nutrition determinants
of later health outcomes.  Am J Clin Nutr 2009, 89:1488S-1493S.
64. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, Zhang
H, Estes A, Brune CW, Bradfield JP, Imielinski M, Frackelton EC,
Reichert J, Crawford EL, Munson J, Sleiman PM, Chiavacci R, Annaiah
K, Thomas K, Hou C, Glaberson W, Flory J, Otieno F, Garris M,
Soorya L, Klei L, Piven J, Meyer KJ, Anagnostou E, Sakurai T, et al.:
Autism genome-wide copy number variation reveals ubiqui-
tin and neuronal genes.  Nature 2009, 459:569-573.
65. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago
M, Moessner R, Pinto D, Ren Y, Thiruvahindrapduram B, Fiebig A,
Schreiber S, Friedman J, Ketelaars CE, Vos YJ, Ficicioglu C, Kirkpatrick
S, Nicolson R, Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat
D, Weksberg R, Thompson A, Vardy C, Crosbie V, Luscombe S,
Baatjes R, et al.: Structural variation of chromosomes in autism
spectrum disorder.  Am J Hum Genet 2008, 82:477-488.
66. Bolton PF, Pickles A, Murphy M, Rutter M: Autism, affective and
other psychiatric disorders: patterns of familial aggregation.
Psychol Med 1998, 28:385-395.
67. Heilstedt HA, Shahbazian MD, Lee B: Infantile hypotonia as a
presentation of Rett syndrome.  Am J Med Genet 2002,
111:238-242.
68. Nagarajan RP, Hogart AR, Gwye Y, Martin MR, LaSalle JM: Reduced
MeCP2 expression is frequent in autism frontal cortex and
correlates with aberrant MECP2 promoter methylation.  Epi-
genetics 2006, 1:e1-11.
69. Caldwell HK, Young WS III: Oxytocin and vasopressin: genetics
and behavioral implications.  In Handbook of Neurochemistry and
Molecular Neurobiology Neuroactive Proteins and Peptides 3rd edition.
Edited by: Lim R. New York, USA: Springer; 2006. 
70. Insel TR: Oxytocin - a neuropeptide for affiliation: evidence
from behavioral, receptor autoradiographic, comparative
studies.  Psychoneuroendocrinology 1992, 17:3-35.
71. Insel TR, Shapiro LE: Oxytocin receptor distribution reflects
social organization in monogamous and polygamous voles.
Proc Natl Acad Sci USA 1992, 89:5981-5985.
72. Insel TR, Winslow JT, Williams JR, Hastings N, Shapiro LE, Carter CS:
The role of neurohypophyseal peptides in the central medi-
ation of complex social processes - evidence from compara-
tive studies.  Regul Pept 1993, 45:127-131.
73. Insel TR, Young L, Wang Z: Central oxytocin and reproductive
behaviours.  Rev Reprod 1997, 2:28-37.
74. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT:
Social amnesia in mice lacking the oxytocin gene.  Nat Genet
2000, 25:284-288.
75. Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T,
Yanagisawa T, Kimura T, Matzuk MM, Young LJ, Nishimori K: Perva-
sive social deficits, but normal parturition, in oxytocin recep-
tor-deficient mice.  Proc Natl Acad Sci USA 2005, 102:16096-16101.
76. Sun L, Huang L, Nguyen P, Bisht KS, Bar-Sela G, Ho AS, Bradbury CM,
Yu W, Cui H, Lee S, Trepel JB, Feinberg AP, Gius D: DNA methyl-
transferase 1 and 3B activate BAG-1 expression via recruit-
ment of CTCFL/BORIS and modulation of promoter histone
methylation.  Cancer Res 2008, 68:2726-2735.
77. Winslow JT, Insel TR: The social deficits of the oxytocin knock-
out mouse.  Neuropeptides 2002, 36:221-229.
78. Zhao X, Leotta A, Kustanovich V, Lajonchere C, Geschwind DH, Law
K, Law P, Qiu S, Lord C, Sebat J, Ye K, Wigler M: A unified genetic
theory for sporadic and inherited autism.  Proc Natl Acad Sci USA
2007, 104:12831-12836.
79. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S,
Seckl JR, Dymov S, Szyf M, Meaney MJ: Epigenetic programming
by maternal behavior.  Nat Neurosci 2004, 7:847-854.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/7/62/prepub